Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
In the I-SPY2.2 trial, patients with high-risk stage 2/3 breast cancer received neoadjuvant datopotamab–deruxtecan, followed by sequential chemotherapy with or without targeted therapy, with the option of early surgical resection after each block of therapy. In a subgroup of patients, the sequential treatment strategy was superior to standard of care.
In the I-SPY2.2 trial, patients with high-risk stage 2/3 breast cancer received neoadjuvant datopotamab–deruxtecan plus durvalumab, followed by sequential chemotherapy with or without targeted therapy, with the option of early surgical resection after each block of therapy, showing that de-escalation of therapy is possible for several patient subgroups without compromising outcome and avoiding toxicity of standard chemotherapy.
A novel application of antisense oligonucleotide (ASO) technology, developed to treat a single patient, adds to the growing number of ‘personalized’ therapies for rare diseases; but pathways to implementation and access are urgently needed.
Post-approval evidence generation is essential for high-quality clinical care and should be a shared priority for clinicians, health systems, payors, and the medical products industry, as well as the FDA and federal agencies.
In the non-randomized phase 3b/4 DESTINY-Breast12 study, trastuzumab deruxtecan (T-DXd) treatment of patients with HER2+ advanced breast cancer and active or stable brain metastases showed consistent intracranial activity and systemic efficacy of T-DXd.
In people undergoing medical abortion after 12 weeks of pregnancy, those who took the first dose of misoprostol at home were less likely to require overnight hospitalization.
Incorporating a series of analytical steps, from data extraction and quality control to the generation of low-dimensional representations and to longitudinal analyses, an open-source software is proposed to standardize current electronic health record data processing and analysis pipelines.
In a first-in-human trial of a triple combination of broadly neutralizing antibodies in people living with HIV, 83% of participants maintained virologic suppression for the duration of antibody therapy, with 42% showing virologic suppression for at least 38–44 weeks, despite the decline of serum antibody concentrations to low or undetectable levels.
Analysis of data related to the Ukraine famine of 1932–1933 shows that in utero exposure to famine increases the risk of adult type 2 diabetes by more than twofold.
A study uses '-omics' and artificial intelligence to derive a metric that distinguishes normal immunity from its perturbation — and reveals that healthy immune systems are less alike than anticipated.
Data collected from 138,015 hospital-based singleton births in four sub-Saharan African countries revealed an association between heat exposure in the week leading up to the birth and perinatal mortality.
